All @ efficacy endpoints met the @ % noninferiority margin : the primary composite endpoint ( @ % vs @ % ; @ % confidence interval -LSB- CI -RSB- , -@ to @ ) , investigator-assessed clinical cure ( @ % vs @ % ; @ % CI , -@ to @ ) , and proportion of patients attaining @ % reduction in lesion area ( @ % vs @ % ; @ % CI , -@ to @ ) for oritavancin vs vancomycin , respectively .